Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.

Abstract

BACKGROUND:

Gemcitabine (GEM) is the first-line chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress responsive transcription factor, is an important contributor to chemoresistance and poor prognosis of PDAC. Brucein D (BD), a naturally occurring quassinoid, has been reported to exert anti-tumor effect in several cancers including PDAC. In this study, we aimed to investigate the efficacy of BD and the role of Nrf2 axes on the chemosensitivity of GEM and elucidate the underlying molecular mechanisms.

METHODS:

Analyses of clinical samples of PDAC and GEPIA database were first conducted to identify the expression of Nrf2 in PDAC. We then established cell lines with stable deletion of Nrf2 through transfecting lentivirus into PDAC cells. Quantitative real-time PCR (qRT-PCR) and Western blotting were performed to determine the expression of Nrf2 in these cell lines. The effects of BD and Nrf2 axes on PDAC cell proliferation, colony-formation, tumor growth and chemosensitivity were determined both in vitro and in vivo. Orthotopic xenograft and genetically engineered KPC mouse models of PDAC were used to evaluate the anti-pancreatic cancer effects of BD and GEM.

RESULTS:

Nrf2 was highly expressed in PDAC in the clinical samples and GEPIA analysis. Gain- and lost-function study demonstrated that Nrf2 affected the chemosensitivity of GEM on PDAC cells both in vitro and in vivo. We further found that BD effectively inhibited PDAC cell proliferation and enhanced the chemosensitivity of GEM. Mechanistic studies revealed that BD sensitized GEM in PDAC cells through the ubiquitin-proteasome-dependent degradation of Nrf2, and downregulating the Nrf2 pathway. Silencing of Nrf2 plus BD treatment resulted in more potent inhibitory effects of GEM. In contrast, Nrf2 activation attenuated the chemosensitivity of GEM, indicating that the action of BD was Nrf2 dependent. Finally, the efficacy of BD alone and in combination with GEM on PDAC was validated on both orthotopic xenograft and genetically engineered KPC mouse models.

CONCLUSIONS:

BD was able to enhance the chemosensitivity of GEM in PDAC through inhibition of the Nrf2 pathway. Our experimental findings indicate that BD, a potent Nrf2 inhibitor, holds promise for further development into a novel adjuvant therapy for PDAC.

• Authors: Juan Zhang, Hong-Xi Xu, William Chi Shing Cho, Wah Cheuk, Yang Li, Qiong-Hui Huang, Wen Yang, Yan-Fang Xian, Zhi-Xiu Lin
• Journal: Journal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 41 Issue 1 Pg. 90 (Mar 10 2022) ISSN: 1756-9966 [Electronic] England
• PMID: 35272669 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Antimetabolites, Antineoplastic
• NF-E2-Related Factor 2
• Quassins
• Deoxycytidine
• bruceine D
• Gemcitabine

Topics

• Animals
• Antimetabolites, Antineoplastic (pharmacology, therapeutic use)
• Cell Line, Tumor
• Deoxycytidine (analogs & derivatives, pharmacology, therapeutic use)
• Female
• Humans
• Mice
• Mice, Nude
• NF-E2-Related Factor 2 (metabolism)
• Pancreatic Neoplasms (drug therapy, mortality, pathology)
• Quassins (pharmacology, therapeutic use)
• Survival Analysis
• Transfection
• Gemcitabine